Abstract: Objective To analyze the changes in serum levels of macrophage inflammatory protein 3α (MIP-3α), serum amyloid A1 protein (SAA1), and glycogen synthase kinase-3β (GSK-3β) in patients with acute coronary syndrome (ACS) and their clinical significance. Methods The data of 162 ACS patients admitted to Henan Hongli Hospital from February 2023 to February 2024 were retrospectively collected and served as the research subjects. Furthermore, based on the Gensini score, patients were categorized into severe (n=50), moderate (n=46), and mild (n=66) groups according to the degree of coronary artery stenosis. Additionally, 55 healthy individuals who underwent physical examinations during the same period were selected as the healthy group. The levels of serum MIP-3α, SAA1, and GSK-3β were compared among the four groups at admission, and correlation analysis was conducted. The levels of various serum indicators were compared among patients with different prognoses at admission, and their predictive value for patient prognosis was analyzed. Results Comparison of serum MIP-3α, SAA1, and GSK-3β levels at admission among four groups: severe group > moderate group > mild group > healthy group (P<0.05); serum MIP-3α, SAA1, and GSK-3β levels at admission were positively correlated with Gensini scores (P<0.05); patients with poor prognosis had higher levels of MIP-3α, SAA1, and GSK-3β at admission than those with good prognosis (P<0.05); the AUC for predicting poor prognosis in patients based on combined detection of serum MIP-3α, SAA1, and GSK-3β levels at admission was 0.805, which was higher than that based on individual diagnosis of each indicator (P<0.05). Conclusion Patients with ACS exhibit elevated levels of serum MIP-3α, SAA1, and GSK-3β, which are associated with the severity of coronary lesions and prognosis. All three markers can serve as indicators of the severity of ACS and are of significant value in predicting patient prognosis.

Key words: MIP-3α, SAA1, GSK-3β, Acute coronary syndrome

摘要： 目的 分析急性冠脉综合征（ACS）患者血清巨噬细胞炎症蛋白3α（MIP-3α）、淀粉样蛋白A1（SAA1）、糖原合成酶激酶-3β（GSK-3β）水平变化及其临床意义。方法 回顾性收集河南宏力医院2023年2月~2024年2月收治的162例ACS患者资料为研究对象,并且根据Gensini评分将患者按冠状动脉狭窄的程度分为重度组（n=50）、中度组（n=46）、轻度组（n=66）,另选取同期55例健康体检者为健康组;对比4组入院时血清MIP-3α、SAA1、GSK-3β水平,并进行相关性分析;对比不同预后患者入院时血清各指标水平,并分析对患者预后的预测价值。结果 4组入院时血清MIP-3α、SAA1、GSK-3β水平比较;重度组>中度组>轻度组>健康组（P<0.05）;入院时血清MIP-3α、SAA1、GSK-3β均与Gensini评分呈正相关（P<0.05）;预后不良患者入院时MIP-3α、SAA1、GSK-3β水平均高于预后良好患者（P<0.05）;入院时血清MIP-3α、SAA1、GSK-3β水平联合检测对预测患者发生预后不良的AUC为0.805,均高于各指标单独诊断（P<0.05）。结论 ACS患者血清MIP-3α、SAA1、GSK-3β水平升高,并与冠脉病变程度及预后有关,三者均可作为反应ACS病情严重程度的标志物,对预测患者预后具有重要价值。

关键词: MIP-3α, SAA1, GSK-3β, 急性冠脉综合征